These findings have contributed to the development of many PSMA-targeted mAbs-drug conjugates and mAbs-nanoparticles for the precise delivery of anti-tumor agents to prostate cancer cells.179 Mukherjee et al. conjugated the humanized anti-PSMA mAb, Hu-J591, to the surface of magnetic iron oxide nanoparticles (MIONs) and showed that the targeting ability of the optimized J591-MION was five-fold greater for the PSMA-positive cells than for the PSMA-negative cells. This evidence concerns the gene FOLH1 and prostate carcinoma.